AcelRx Pharmaceuticals Inc (ACRX) Receives $4.45 Consensus Price Target from Brokerages
Shares of AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) have been given an average rating of “Hold” by the nine research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $4.45.
ACRX has been the subject of several analyst reports. Roth Capital set a $8.00 price target on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, October 12th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of AcelRx Pharmaceuticals in a research report on Tuesday, October 3rd. Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a research report on Wednesday, December 27th. Jefferies Group lowered shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 13th. Finally, Piper Jaffray Companies restated a “hold” rating and set a $2.00 price target on shares of AcelRx Pharmaceuticals in a research report on Friday, October 13th.
In other news, Director Mark G. Edwards bought 30,000 shares of the company’s stock in a transaction dated Tuesday, November 14th. The stock was bought at an average cost of $1.90 per share, for a total transaction of $57,000.00. Following the completion of the acquisition, the director now owns 150,000 shares in the company, valued at approximately $285,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 28.10% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Perennial Advisors LLC purchased a new stake in shares of AcelRx Pharmaceuticals during the third quarter worth about $138,000. Virtu KCG Holdings LLC raised its stake in AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after buying an additional 101,742 shares in the last quarter. Geller Family Office Services LLC bought a new position in AcelRx Pharmaceuticals in the third quarter worth about $460,000. Finally, Goldman Sachs Group Inc. bought a new position in AcelRx Pharmaceuticals in the second quarter worth about $530,000. Institutional investors own 13.70% of the company’s stock.
AcelRx Pharmaceuticals (NASDAQ ACRX) traded down $0.05 during midday trading on Monday, reaching $2.05. 327,700 shares of the company’s stock traded hands, compared to its average volume of 524,127. The company has a current ratio of 4.78, a quick ratio of 4.71 and a debt-to-equity ratio of -0.43. AcelRx Pharmaceuticals has a twelve month low of $1.55 and a twelve month high of $5.75. The stock has a market capitalization of $103.19, a price-to-earnings ratio of -1.83 and a beta of 2.96.
TRADEMARK VIOLATION WARNING: “AcelRx Pharmaceuticals Inc (ACRX) Receives $4.45 Consensus Price Target from Brokerages” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/01/04/acelrx-pharmaceuticals-inc-acrx-receives-4-45-consensus-price-target-from-brokerages.html.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.